MAINZ BIOMED N.V.MYNZEarnings & Financial Report
Nasdaq
MYNZ Q3 2023 Key Financial Metrics
Revenue
$181.7K
Gross Profit
$87.2K
Operating Profit
$-5.6M
Net Profit
$-6.3M
Gross Margin
48.0%
Operating Margin
-3104.9%
Net Margin
-3467.7%
YoY Growth
87.7%
EPS
$-0.39
Financial Flow
MAINZ BIOMED N.V. Q3 2023 Financial Summary
MAINZ BIOMED N.V. reported revenue of $181.7K for Q3 2023, with a net profit of $-6.3M (-3467.7% margin). Cost of goods sold was $94.5K, operating expenses totaled $5.7M.
Key Financial Metrics
| Total Revenue | $181.7K |
|---|---|
| Net Profit | $-6.3M |
| Gross Margin | 48.0% |
| Operating Margin | -3104.9% |
| Report Period | Q3 2023 |
Income Statement
| Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|
| Revenue | $139240 | $96791 | $1 | $248945 | $181669 |
| YoY Growth | N/A | N/A | N/A | 78.8% | 87.7% |
Balance Sheet
| Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|
| Assets | $27.6M | N/A | $19.5M | $19.3M | $17.9M |
| Liabilities | $3.8M | N/A | $9.9M | $14.1M | $14.5M |
| Equity | $23.8M | $20.8M | $9.7M | $5.2M | $3.4M |
Cash Flow
| Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|
| Operating CF | $-3.7M | $-3.6M | $-5.7M | $-5.1M | $-6.5M |